It is possible even if not probable. BioAmber fits the product...depends on if it's viewed negatively in the sector...or just the management. I could see a scenario where its ends up a subsidiary.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.